The U.S. Food and Drug Administration (FDA), two months after approving the subcutaneous version of the lung cancer drug Rybrevant — Rybrevant Faspro (amivantamab + hyaluronidase) — has authorized a “simplified” dosing regimen for it. The drug from Johnson & Johnson can now be administered once a month, whereas previously it was given every two weeks.
Rybrevant Faspro in combination with lazertinib is used as a first-line therapy for advanced non-small cell lung cancer with EGFR mutations. The new dosage can be prescribed starting from the fifth week of treatment.” Based on the unprecedented high overall survival and predictable safety profile, the monthly injection provides the simplest and fastest combination therapy for patients with EGFR-mutated non-small cell lung cancer,” stated Mahadi Baig, Vice President of U.S. Medical Affairs at Johnson & Johnson.
Since December of last year, Rybrevant Faspro has been approved for use for the same indications as the original intravenous form, Rybrevant.
